Progress in the use of gadolinium for NCT

Cerullo, N.; Bufalino, D.; Daquino, G.G.

doi:10.1016/j.apradiso.2009.03.109

Cited by 43 publications

(43 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…with details of the decay processes (Ali et al, 1994, Becvar et al, 2000, Cerullo et al, 2009, Groshev et al, 1958, Kandlakunta et al, 2013, Kinsey and Bartholomew, 1953, 7e12, Sakurai and Kobayashi, 2002, Schultz et al, 2010 now nicely summarized in (Schultz et al, 2010). A similar result occurs with the neutron capture process 155 Gd(n,g) 156 Gd.…”

Section: Introductionmentioning

confidence: 61%

“…The Gd cross section remains significantly higher than the thermal neutron capture cross section of 10 B out to neutron energies of w200 meV. Because of the large natural Gd thermal neutron capture cross section of 46,000 b, including a 15.65% natural abundance of the 157 Gd isotope with a thermal neutron capture cross section of 255,000 b (Cerullo et al, 2009, Garber and Kinsey, 1976, Gebauer et al, 1997, KAERI 2000, McLane et al, 1988, Mireshghi et al, 1994, Gd has often been touted as the primary conversion component of a neutron detector (Ali et al, 1994, Becvar et al, 2000, Groshev et al, 1958, Kandlakunta et al, 2013, Kinsey and Bartholomew, 1953, 7e12, Sakurai and Kobayashi, 2002, Schultz et al, 2010. The 157 Gd isotope neutron absorption of the neutron leaves the 158 Gd in an excited state that releases energy through emission of high and low energy gamma rays, X-rays, and internal conversion (IC) and Auger Coster-Kronig (ACK) conversion electrons as:…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Gamma and X-ray sensitivity of Gd2O3 heterojunctions

Santana

Young

McClory

et al. 2013

Radiation Measurements

View full text Add to dashboard Cite

Young, C M.; McClory, J W.; Petrosky, J C.; Wang, X; Liu, P; Tang, Jinke; Adamiv, V T.; Burak, Ya V.; Fukutani, Keisuke; and Dowben, Peter A., "Gamma and X-ray sensitivity of Gd 2 O 3 heterojunctions" (2013 b s t r a c tWe find that Gd 2 O 3 thin films strongly favor a (À402) texture growth on a variety of substrates and will form heterojunction diodes with silicon, especially when doped with oxygen vacancies. Even in the thin film limit, these heterojunction diodes appear to be sensitive to gamma radiation, likely from the X-rays created by scattering events, adding to the numerous hurdles that must be overcome if Gd based semiconductor devices are to be used for solid state neutron detection applications.

show abstract

Section: Introductionmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 97%

Gamma and X-ray sensitivity of Gd2O3 heterojunctions

Santana

Young

McClory

et al. 2013

Radiation Measurements

View full text Add to dashboard Cite

show abstract

“…If the tumor-accumulating nano-particle containing Gd was developed and usable for NCT safely and an effectively, it would be possible application as an adjuvant to BNCT. For effective Gd NCT, it is necessary that the Gd is existed near the tumor, and the concentration of Gd in the tumor is more than 100 ppm (Cerullo et al, 2009;Horiguchi et al, 2011). In this study, we had clarified that Gd was located uniformly in tumor.…”

Section: Discussionmentioning

confidence: 95%

“…From the radiation therapeutic point of view, the long-range γ-rays will deliver dose to the surrounding normal tissue, which reduces the localization effect of NCT but also increase the effect of hitting around the invading malignant cells. In addition, Auger electrons may increase the effective Relative Biological Effectiveness (RBE) and substantially improves its overall therapeutic effects (De, Stasio et al, 2001;Tokumitsu et al, 2000;Cerullo et al, 2009). Suitable concentration of Gd-NCT combined with BNCT, extensive effect to surrounding normal tissue and tumors has a possibility to gain tumor control rate.…”

Section: Introductionmentioning

confidence: 97%

Intra-tumor distribution of metallofullerene using micro-particle induced X-ray emission (PIXE)

Yamamoto

Horiguchi

et al. 2014

Applied Radiation and Isotopes

View full text Add to dashboard Cite

“…However, if 157 Gd uptake is strictly limited to tumor bulk and considering a tumor volume of the order of some cm 3 , these rays can produce an additional positive effect that is to increase the radiation dose to the tumor also if the NCT agent is not intracellularly distributed, lowering the requirement of uptake by the cell nucleus. [19,20].…”

Section: 8%) and 157mentioning

confidence: 99%

Insights into the Use of Gadolinium and Gadolinium/Boron-Based Agents in Imaging-Guided Neutron Capture Therapy Applications

et al. 2016

View full text Add to dashboard Cite

Gadolinium neutron capture therapy (Gd-NCT) is currently under development as an alternative approach for cancer therapy. All of the clinical experience to date with NCT is done with 10 B, known as BNCT, a binary treatment combining neutron irradiation with the delivery of boron-containing compounds to tumors. Currently, the use of gadolinium for NCT has been getting more attention because of its highest neutron cross-section. Although Gd-NCT was first proposed many years ago, its development has suffered due to lack of appropriate tumor-selective Gd-agents. This review aims to highlight the recent advances for the design, synthesis and biological testing of new Gd-and B-Gd-containing compounds with the task of finding the best systems able to improve the NCT clinical outcome. Keywords:Gadolinium Neutron Capture Therapy, Boron Neutron Capture Therapy, MRI, Gd contrast agents, Tumor Treatment, Nanosized Gd agents. 3 General introduction on NCT: rationale and applicationNeutron Capture Therapy (NCT) is a non-conventional radiotherapy that combines low energy neutron irradiation with the presence of a neutron-absorbing substance at the targeted cells [1][2].Two isotopes are of major interest because of their large capture cross section: head and neck recurrent cancer [6][7], melanoma [8] and adenocarcinoma liver metastases [9]; ii) sodium mercaptoundecahydro-closo-dodecaborate (BSH) that has been investigated for the treatment of malignant glioma [10]. Despite their clinical use and the safe and effective BNCT, trials performed with these two drugs until now, both BPA and BSH show low selectivity and great efforts have been made by several research groups to develop new and more selective boron delivery agents [11][12].The use of BNCT to destroy malignant cells was proposed long time ago [13]. In spite of huge promises, it has not attained an established position in the mainstream medicine.However, the methodology has never been discarded and it remains in an intermediate state with a small group of enthusiast supporters and many critical spectators. The reasons why BNCT has not maintained the original promises rely mainly in the lack of properly designed agents. The conditions for an effective therapeutic output are well established: the BNCT agent must reach selectively a given concentration inside cells and the not-attainment of this task makes the therapy less effective. Only a proper NCT agent design (based on an improved knowledge on how molecules enter healthy and diseased cells) allows to reach selectively the needed threshold of intracellular concentration required to drive the breakthrough of BNCT in the field of conventional and diffused treatments for cancer. Moreover, the in vivo assessment of the amount of NCT agent can now be tackled by its conjugation to a suitable imaging-reporter. [14][15] To date there is no non-invasive means to evaluate boron concentration in tumor and healthy tissues of the subject undergoing the irradiation. Thus, dose calculations are based on boron content values in...

show abstract

Progress in the use of gadolinium for NCT

Cited by 43 publications

References 6 publications

Gamma and X-ray sensitivity of Gd2O3 heterojunctions

Gamma and X-ray sensitivity of Gd2O3 heterojunctions

Intra-tumor distribution of metallofullerene using micro-particle induced X-ray emission (PIXE)

Insights into the Use of Gadolinium and Gadolinium/Boron-Based Agents in Imaging-Guided Neutron Capture Therapy Applications

Contact Info

Product

Resources

About